Genetic and Pharmacologic Inhibition of eIF4E Reduces Breast Cancer Cell Migration, Invasion, and Metastasis

These findings offer a powerful rationale to broaden the clinical evaluation of ribavirin, a small molecule inhibitor of the translation initiation factor eIF4E currently being tested in leukemia patients, as a strategy to treat advanced solid tumors such as metastatic breast cancer in which eIF4E is commonly overexpressed.